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Stem cell transplantation is used widely in the management of a range of diseases of the 
hemopoietic system. Patients are immunosuppressed profoundly in the early posttransplant 
period, and reactivation of cytomegalovirus (CMV) remains a significant cause of morbidity 
and mortality. Adoptive transfer of donor-derived CMV-specific CD8
 
 
 
 T cell clones has been 
shown to reduce the rate of viral reactivation; however, the complexity of this approach 
severely limits its clinical application. We have purified CMV-specific CD8
 
 
 
 T cells from the 
blood of stem cell transplant donors using staining with HLA–peptide tetramers followed by 
selection with magnetic beads. CMV-specific CD8
 
 
 
 cells were infused directly into nine 
patients within 4 h of selection. Median cell dosage was 8.6 
 
 
 
 10
 
3
 
/kg with a purity of 98% 
of all T cells. CMV-specific CD8
 
 
 
 T cells became detectable in all patients within 10 d of 
infusion, and TCR clonotype analysis showed persistence of infused cells in two patients 
studied. CMV viremia was reduced in every case and eight patients cleared the infection, 
including one patient who had a prolonged history of CMV infection that was refractory to 
antiviral therapy. This novel approach to adoptive transfer has considerable potential for 
antigen-specific T cell therapy.
 
CMV reactivation is a significant clinical problem
after allogeneic stem cell transplantation (SCT;
reference 1). Antiviral drugs can reduce the inci-
dence of early-onset CMV disease, but are asso-
ciated with substantial toxicity and the devel-
opment of late-onset CMV disease. CMV
reactivation arises because of impaired CMV-
specific immunity and CD8
 
 
 
 CTLs are believed
to play the predominant role in suppressing viral
replication. This has led to the development
of clinical protocols whereby CMV-specific
CD8
 
 
 
 T cell clones are cultured from the trans-
plant donor and transferred to the patient after
transplantation (2–5). This has proven effective
in the prevention of reactivation and treatment
of CMV infection that is unresponsive to anti-
viral therapy. However, this procedure has not
been adopted widely because of the significant
technical and financial demands of extensive ex
vivo T cell culture.
CMV-specific CD8
 
 
 
 T cells are found at
high frequency in the blood of healthy
CMV-seropositive individuals and typically
represent 0.5–4% of the CD8
 
 
 
 T cell pool
(6). Magnetic beads allow the selection of anti-
gen-specific T cells using HLA–peptide tetra-
mers (7); this offers the prospect of selecting
CMV-specific CD8
 
 
 
 T cells directly from
the blood of transplant donors and transfer-
ring them into the patients without ex vivo
manipulation. Here, we have selected CMV-
specific T cells from nine SCT donors and in-
fused these directly into transplant recipients.
Adoptive transfer was followed by consider-
able expansion of CMV-specific CTLs in
vivo and subsequent control of viremia.
 
The online version of this article contains supplemental material.
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RESULTS AND DISCUSSION
CMV-specific CTLs can be purified by HLA–peptide 
tetramers and remain functional
 
CMV-specific CTLs were selected from CMV-seropositive
donors by staining PBMCs with HLA–peptide tetramers
containing peptides from CMV pp65 or IE-1, followed by
selection using magnetic beads. 10 healthy CMV-seroposi-
tive laboratory donors were recruited to evaluate the effi-
ciency of large-scale selection. 0.41–12.3% (median 2.5%) of
CD8
 
 
 
 T cells stained with tetramer before selection. This
increased to 97.8–99.9% (median 98.8%) after positive selec-
tion (Fig. 1 A), and represented a median of 94% of the total
live cell population. The sensitivity of selection was good; an
average of 61% of CMV-specific CTLs was recovered. The
functional activity and proliferative potential of positively se-
lected CTLs was confirmed in vitro (Fig. 1, B–D).
 
CMV-specific CTLs may be administered directly to patients 
after selection
 
Nine patients were treated with adoptive therapy; six pa-
tients had received the transplant from an HLA-matched
sibling and three patients had received stem cells from an
Figure 1. Selection of CMV-specific CTLs from blood samples using 
large-scale magnetic separation. (A): HLA–peptide tetramer staining of 
donor PBMCs before selection and in the positive and negative fractions 
after selection. (B) Cytotoxicity assay of positively selected cells performed 
directly after selection or after 8 d of culture on autologous peptide-loaded 
cells.  , 0.5  M peptide;  , DMSO control. (C) Growth characteristics of 
cells in the positive fraction reveal a 30-fold expansion after 8 d. Cells 
were expanded with autologous lymphoblastoid cells and allogeneic 
feeder cells. (D) Positively selected CMV-specific CTLs lyse autologous and 
HLA-matched fibroblasts, which have been infected with CMV. CTLs were 
cultured for 8 d and subsequently were tested on fibroblasts that were 
infected with CMV. The E:T ratio in all cases was 2:1.  , Mock-infected 
fibroblasts;  , CMV-infected fibroblasts. All results are representative of 
at least three independent experiments. 
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HLA-unrelated donor (Table I). The first six patients and
patient 9 received adoptive transfer of CTLs after the initial
episode of viral reactivation, whereas patients 7 and 8 were
treated for persistent viremia. CMV-specific CTLs were se-
lected from 250 ml of peripheral blood or a leukapheresis
product from the stem cell donor. Positively selected cells
were infused into patients within 4 h of selection. 1.2 
 
 
 
10
 
3
 
/kg to 3.3 
 
 
 
 10
 
4
 
/kg of selected CTLs were administered
with a median T cell purity of 95.6% (Table I). No toxicity
was observed after cell infusion.
 
CMV-specific immune reconstitution was observed 
after infusion of CMV-specific CTLs
 
Immune reconstitution of CMV-specific CTLs was mon-
itored by staining blood samples with HLA–peptide tet-
ramer before infusion and after adoptive transfer. Exam-
ples of viral load and immune recovery in the first three
patients are shown in Fig. 2; complete data are presented
in Table I. CMV-specific CTLs were detected in all pa-
tients after adoptive transfer and were maintained during
the follow-up period of up to 24 mo. The peak CTL re-
sponse was seen between 12 and 30 d after adoptive trans-
fer with a range of 1–156 cells/
 
 
 
l of blood. Persistence of
infused cells was determined using the TCR CDR3 se-
quence of the infused cells as a clonotypic marker. Analy-
sis was possible only in patients 2 and 7 because of limited
availability of patient and donor samples. No clonotype-
specific T cells were detectable in either patient before
adoptive transfer but they were present at every time
point after immunotherapy (Fig. 2 B; see Fig. 3 C). Pa-
tient 2 demonstrated persistence of CTLs to at least 100 d
after infusion, and the intensity of the PCR product in-
creased over time in both patients, which suggested ex-
pansion of the infused cells.
The functional activity of CMV-specific CTLs was mea-
sured by the use of intracellular staining for IFN-
 
 
 
 after peptide
stimulation. IFN-
 
 
 
–producing cells were seen at an early time
point after adoptive transfer, although the proportion of tet-
ramer-binding cells that expressed IFN-
 
 
 
 gradually increased
in the first 6 mo after transfer (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20040613/DC1).
 
Reduction in CMV viremia was seen in all patients
 
CMV viral load was monitored weekly after the first episode
of reactivation. In the first seven patients and patient 9,
CMV reactivation resolved completely after adoptive trans-
fer of CTL. Patient 8 documented marked reduction in
CMV viral load in association with CMV-specific immune
reconstitution. No case of CMV disease was seen.
Of the six patients who received stem cells from a sibling
donor, four did not require antiviral therapy; however, in
accordance with the trial protocol, two patients (33%) were
treated with ganciclovir (GCV) after adoptive transfer, one
of whom had received corticosteroids within 1 wk of ther-
apy. In comparison, GCV was required in 9 of 11 patients
(81.8%) in a control group who did not receive adoptive
transfer during the same period. The difference in the pro-
portion of patients who required GCV was 48%; the 95%
confidence interval for this value is 4–93%. This confidence
interval is wide and reflects the small number of patients in
the trial; however, the fact that it remains above zero indi-
cates that it is highly likely that treatment does reduce the
proportion of patients who require GCV treatment.
CMV-specific immune reconstitution is known to be
impaired markedly in patients who receive stem cells from
an unrelated donor (8); the three patients with unrelated do-
nors in our study were particularly informative in demon-
strating the therapeutic potential of adoptively transferred
 
Table I.
 
Virology, cell selection, treatment, and immune recovery data
 
Clinical details Selection data Outcome
Patient
Primary
diagnosis
Transplant
protocol
Day cells
infused ALC at infusion 
Specificity
infused
Total cells
infused/kg Purity 
Day after
infusion
of CTL peak
Peak
CTL
Maximum
grade
of GvHD
Antiviral
administration
 
 
 
 10
 
9
 
L % CD3
 
 
 
 cells tetramer
 
 
 
 cells/
 
 
 
l
 
1 WM BC 40 0.1 NLV 3.1 
 
 
 
 10
 
3
 
98.5 12 8.4 0 yes
2 AML FMC 18 0.3 YSE 1.47 
 
 
 
 10
 
4
 
92.6 18 156 0 no
3 CLL FMC 23 1.1 YSE 3.1 
 
 
 
 10
 
3
 
95.6 19 42 0 no
4 CML Cy, TBI 34 0.8 YSE 
 
 
 
 ELR 1.23 
 
 
 
 10
 
3
 
99.5 16 15 II yes
5 HD FMC 29 0.4 TPR 
 
 
 
 NLV 1.67 
 
 
 
 10
 
3
 
88.0 27 44 I no
6 CML Cy, Bu 55 0.6 NLV 8.6 
 
 
 
 10
 
3
 
98.0 4 101 0 no
7
 
a
 
CML Cy, TBI 246 1.2 NLV 3.3 
 
 
 
 10
 
4
 
99.2 6 2 0 pretherapy
8
 
a
 
ALL Cy, TBI 247 0.55 IPS 1.22 
 
 
 
 10
 
4
 
10
 
b
 
26 1.1 0 pretherapy
9 ALL FMC 21 0.2 ELR 1.0 
 
 
 
 10
 
4
 
95.4 114 105 II pretherapy
 
a
 
Patient 7 had been refractory to ganciclovir and patient 8 had been refractory to cidofovir.
 
b
 
Purity was reduced due to the low frequency of the CMV-specific CD8
 
 
 
 T cells in the donor (0.08% of CD8
 
 
 
 cells). The depletion of cells not binding tetramer was 
 
 
 
3 log. CMV 
epitopes are as follows: ELR-IE1
 
199-207
 
; IPS-pp65
 
123-131
 
; NLV – pp65
 
495-503
 
; TPR-pp65
 
417-426
 
; YSE-pp65
 
363-373
 
.
ALC, absolute lymphocyte count; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BC, BEAM/Campath-1H; Bu, busulfan; CLL, chronic lymphocytic leukemia; 
CML, chronic myeloid leukemia; Cy, cyclophosphamide; FMC, fludarabine melphalan Campath-1H; HD, Hodgkin’s disease; TBI, total body irradiation; WM, Waldenström’s 
macroglobulinemia. 
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CTLs (Fig. 3). Patient 7 had developed primary CMV infec-
tion and experienced 4 mo of persistent CMV reactivation
that was refractory to three antiviral agents. No CMV-spe-
cific immunity was demonstrable before therapy, but CMV-
specific CTLs became detectable 4 d after infusion, and the
CMV reactivation was controlled at 11 d after infusion. Pa-
tient 8 had experienced CMV viremia for 10 wk before
adoptive transfer and possessed no endogenous CMV-spe-
cific immunity. Adoptive therapy was given at day 247 after
transplant and was followed by the appearance of CMV-spe-
cific CTLs in peripheral blood 7 d after transfer. Cidofovir
was administered before therapy, and CMV viremia was
controlled but remained detectable for several weeks before
a fatal episode of bacterial sepsis. Patient 9 gained prompt
immune reconstitution after adoptive transfer and long-term
control of viremia.
Figure 2. CMV-specific immune reconstitution and CMV viremia 
after adoptive transfer of CMV-specific CTLs. The vertical bar indicates 
the timing of adoptive transfer and the absolute number of CMV-specific 
CTLs administered. Data from patients 1, 2 and 3 (A–C) are shown.  , Abso-
lute count of tetramer  T cells;  , viral load. Persistence of the infused T cells 
was assessed in patient 2 by PCR detection of the clonotypic TCR CDR3 
sequence of the infused cells in PBMC samples that were taken from the 
patient. FACS analysis of donor PBMCs demonstrated that 80% of the CMV-
specific CTLs expressed the TCRBV11 chain. TCRBV11-specific PCR was per-
formed on positively selected donor CMV-specific CTLs, and the PCR prod-
ucts were cloned and sequenced to determine the dominant TCR clonotype. 
A single TCR CDR3 sequence, YLCARFDGRAGETQYFGPG, comprised 90% of 
all TCRBV11 sequences. A clonotype-specific primer (5 -gtttgacgggagggc-
cggtga–3 ) was synthesized and used with a TCRBC primer for clonotype-
specific PCR which was performed on patient PBMCs that were isolated 
before infusion and at days 5, 28, 44, 66, and 100 after infusion. 
JEM VOL. 202, August 1, 2005
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Figure 3. CMV-specific immune reconstitution and CMV viremia 
after adoptive transfer of CMV-specific CTLs in patients. The vertical 
bar indicates the timing of adoptive transfer and the absolute number of 
CMV-specific CTLs that was administered. Data from patients 7, 8, and 9 
(A–C) is shown.  , Absolute count of tetramer  T cells or expressed as 
percentage of CD8 T cells;  , viral load. Persistence of the infused T cells 
was assessed in patient 7 by PCR detection of the clonotypic TCR CDR3 
sequence of the infused cells in PBMC samples that were taken from 
the patient (Fig. 2);  90% of tetramer-binding cells expressed TCRBV3. 
A single TCR CDR3 sequence, SGEQGMDEQYFGPGTRLTVT, made up all 
TCRBV3 sequences. A clonotype-specific primer (5 -gggaacagggaatggac-
gag–3 ) was used for clonotype-specific PCR that was performed on 
patient PBMCs that were isolated before infusion and at days 1, 5, 7, 12, 
and 15 after infusion (A). 
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Reactivation of CMV after SCT is a consequence of the
profound state of immunosuppression which is seen in pa-
tients early after transplant. This results from transplant condi-
tioning protocols and the use of immunosuppressive drugs to
suppress graft versus host disease (GvHD). It was demon-
strated clearly that donor-derived CMV-specific CTLs that
have been isolated and expanded in vitro may be administered
to transplant patients and can control viral reactivation (2).
However, only clinical units with considerable expertise can
adopt such a therapy. Here, we have used HLA–peptide tet-
ramers to transfer antigen-specific CTLs directly from the do-
nor into patients without the requirement for in vitro culture.
CMV-specific CD8
 
 
 
 CTLs are found at high frequency
in the peripheral blood of CMV-seropositive donors (6, 9),
and magnetic beads can be used to select these CTLs (7, 10).
We have demonstrated that this approach can be scaled up
for processing of large samples of blood or leukapheresis
specimens. The procedure occurs in a “closed” system using
equipment that is used routinely for processing stem cell har-
vests; after selection, the CMV-specific CTL represented
 
 
 
95% of live cells.
CMV-specific T cells were administered to nine patients
and no side effects were observed. Two patients exhibited
mild GvHD (grades 1 and 2) within 2 wk of transfer, but
grade 1 GvHD was present in both patients before infusion.
The lack of significant GvHD reflects transfer of a very low
number of T cells with antigenic specificity other than that
for CMV. A total dose of 1.2 
 
 
 
 10
 
4
 
 to 2 
 
 
 
 10
 
6
 
 CMV-spe-
cific T cells was administered; this is much smaller than in
other adoptive transfer protocols where up to 10
 
9
 
 T cells are
given. However, this number may be sufficient to control
viral reactivation. Transfer of only 10
 
6
 
/kg PBMCs has been
used to control posttransplant lymphoproliferative disease
that is due to EBV infection (11). The frequency of EBV-
specific CTLs within PBMCs is comparable to that of
CMV-specific CTLs (12); this suggests that clinical efficacy
was achieved by transfer of similar numbers of CTLs to that
used in our study. In addition, T cells can expand in vivo by
many orders of magnitude, and there was evidence for this
in our study. Patient 7 had no CMV-specific CTLs before
infusion; however, 6 d after transfer, these CTLs had ex-
panded to 2 
 
 
 
 10
 
6
 
/l and represented 10
 
7
 
 cells in peripheral
blood. Because only 2% of the lymphocyte pool is located in
the peripheral blood, this suggests a total count of 
 
 
 
5   108
tetramer-binding cells—an expansion of 250-fold from the
starting infusion. It is possible that T cells infused directly
from donor PBMCs may be able to expand more efficiently
in vivo than T cells clones which have been expanded ex-
tensively in vitro before infusion, although massive expan-
sion of infused T cells has been reported after a period of in
vitro culture (13, 14). The lymphopenic environment asso-
ciated with SCT is likely to be favorable for T cell prolifera-
tion, and such a degree of expansion may not be achievable
in other clinical situations.
Selected CTLs were not marked before transfer because
of ethical constraints, but clinical evidence provides support
for their expansion in vivo. Endogenous CMV-specific im-
mune reconstitution can be brisk in patients with sibling do-
nors, but transplants from unrelated donors are associated
with markedly impaired reconstitution within the first 100 d
(8, 15). This is due to T cell depletion of the donor inocu-
lum and increased histoincompatibility between donor and
recipient. All three of the patients with unrelated donors
in our study showed prompt immune reconstitution after
adoptive therapy despite the fact that two patients had suf-
fered from prolonged viremia before treatment.
CTLs were functional after transfer, and our findings in-
dicate that this contributes to the control of viral replication.
This is demonstrated most clearly in patient 7; his CMV reac-
tivation was refractory to antiviral drugs but was controlled
within 8 d of adoptive transfer. Prompt T cell expansion was
seen in all patients, and after resolution of CMV viremia,
there were no subsequent episodes of viral reactivation. The
CMV-specific CD4  T cell response was determined in pa-
tients 1 through 5 and showed no correlation with the degree
of CMV-specific CD8  T cell expansion (Fig. S2, available at
http://www.jem.org/cgi/content/full/jem.20040613/DC1).
The proportion of patients that required GCV is lower
than that seen in a control group, although the degree of
protection is difficult to predict given the small number of
patients involved. This approach is limited to patients who
express HLA alleles for which CMV peptides are available.
However, many CMV epitopes have now been reported
and  75% of the transplant population is eligible for treat-
ment. This therapy is amenable to all situations in which the
transplant donor has T cells that are specific for the antigen
to be targeted in the patient. The most obvious clinical set-
ting is allogeneic SCT; however, successful adoptive transfer
of T cells outside the setting of SCT also was reported (16)
and may be facilitated by tetramer selection. Adoptive trans-
fer of antigen-specific CTLs after selection with HLA–pep-
tide tetramer is a novel approach to adoptive T cell therapy
that offers considerable potential for cellular therapy.
MATERIALS AND METHODS
Patients and transplant protocols. Four patients received standard my-
eloablative conditioning with cyclophosphamide (120 mg/kg) and total
body irradiation (14.4 Gy) or busulfan (56 mg/kg/d for 4 d). Five patients
received the reduced intensity conditioning regimens BEAM CAMPATH-
1H (17) or Flu/Mel/CAMPATH-1H (18). Cyclosporin and short-term
methotrexate were given as prophylaxis against graft versus host disease
(GvHD). Oral acyclovir was administered until day 30 after SCT.
Virus screening and antiviral therapy. Screening for CMV reactiva-
tion was performed once weekly from day 14 by qualitative PCR from
whole blood and continued until day 100 (19). CMV PCR was performed
on the Roche Light Cycler FastStart DNA Master (Roche Molecular Bio-
chemicals) with quantitation over a wide range (4   102 to 5   108 copies/
ml). Patient 7 was monitored using the CMV antigenemia assay, which
quantifies the number of CMV infected cells in the peripheral blood per
200,000 leukocytes.
Protocol design. SCT recipients who received a transplant from a CMV-
seropositive donor were recruited, and written informed consent was ob-
tained from donor and recipient. Approval for this study was obtained fromJEM VOL. 202, August 1, 2005 385
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the South Birmingham Local Research Ethics Committee. Patients who
express the HLA class I alleles HLA-A*0101, HLA-A*0201, HLA-B*0702,
HLA-B*0801, or HLA-B*3502 were eligible for entry. The presence of
CMV-specific CTLs was determined in a blood sample from the donor; if
tetramer-binding cells represented  0.05% of the CD8  population they
were used for large-scale selection. At the first time point of CMV reactiva-
tion, 250 ml of blood was taken from the donor, and the CMV-specific
CTLs were selected. In patients 7 and 8, stored cryopreserved leukapheresis
products were thawed and used to select CMV-specific CTLs. These were
infused into the donor within 4 h. Standard management of CMV reactiva-
tion was not affected by the cell infusion, and GCV (10 mg/kg/d) was
commenced if two positive consecutive CMV PCR tests were obtained.
Selection of CMV-specific CTLs. 250 ml of blood was mixed with an
equal volume of magnetic-activated cell sorting (MACS) buffer (Miltenyi
Biotec) and mononuclear cells were separated using a density gradient
(Lymphoprep; Nycomed). In patients 7 and 8, the thawed leukapheresis
sample was washed in MACS buffer and then treated in the same way. Cells
were resuspended in 2 ml of MACS buffer and 100  g of 0.2  M filtered
HLA–peptide tetramer followed by incubation at 37 C for 15 min. Cells
were washed and resuspended in 2 ml of MACS buffer and 400  l of anti-
PE paramagnetic MicroBeads (Miltenyi Biotec) at 4 C for 30 min. Tet-
ramer-binding cells were selected magnetically using Enrichment 3.1 pro-
gram on the ClinMACSplus cell separator. The positive fraction was eluted
in 40 ml of MACS buffer, of which 2 ml was tested for purity and cell num-
ber by flow cytometry. The remaining 38 ml was infused into the patient
over 15 min. Cells were kept on ice at all times unless otherwise stated and
cell manipulation was performed in a sterile cabinet in a clean room. HLA–
peptide tetrameric complexes were assembled under sterile conditions, and
all reagents were certified as endotoxin free. Microbiologic testing was per-
formed on cells after magnetic selection.
Synthesis and use of tetramers. HLA tetramers were synthesized by the
use of standard methods (20), and the components of the HLA–peptide tetra-
mers that were used in the study are shown in Table I. The percentage of tet-
ramer binding was determined by flow cytometry (EPICS XL, Beckman
Coulter).
Clonotypic PCR analysis. TCR  -chain variable region gene (TCRBV)
usage of donor CMV-specific CTLs was determined initially by FACS anal-
ysis after costaining with tetramer and TCRBV-specific antibodies (BV1–
BV23, Immunotech). Tetramer-binding cells were purified ( 90% purity)
using magnetic selection before extraction of RNA and cDNA synthesis.
TCRVB-specific PCR primers were used to amplify the dominant TCRBV
family, and PCR products were cloned into a TOPO vector (Invitrogen)
and sequenced (21). Clonotypic TCRBV PCR primers were designed
complementary to the CDR3 region of the dominant transcripts. These
primers were used with a TCRBC region primer to identify clonotypic
TCR sequences within cDNA samples generated from unselected patient
PBMCs that were taken at multiple time points before and after infusion of
selected CTLs.
Statistical analysis. Statistical comparison was made between the propor-
tion of patients in the study group who required treatment with GCV and
those in a control group of inappropriate HLA type or donor unavailability.
Because some of the expected frequencies were  5, the chi-square test was
not believed to be valid and a 95% confidence interval was determined for
the difference in the proportions who required treatment.
Online supplemental material. Fig. S1 shows the functional compe-
tence of CMV-CTL. Fig. S2 shows CMV-specific CD4 T cell immune
reconstitution. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20040613/DC1.
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